688578.SH
艾力斯
SSE · Healthcare · Biotechnology · CN
CNY 112.19
−3.70%Year over year
Reported trailing growth
- Revenue
- +45.0%
- EBITDA
- —
- EBIT
- +58.8%
- EPS
- +57.4%
- Free cash flow
- +78.9%
- Operating cash flow
- +55.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +87.2%
- EBITDA
- +159.8%
- EBIT
- +172.4%
- Net income
- +156.0%
- EPS
- +155.9%
- Free cash flow
- +87.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026